European firm BioGX BV has announced a new test that detects COVID-19, Influenza A and B and other viruses in one sample.
The firm is a Netherlands-based subsidiary of BioGX, which is headquartered in Birmingham. However, the test is not available for sale or use in the U.S.
The BioGX test detects COVID-19, Influenza A and B and RSV from pharyngeal and nasopharyngeal swabs, using reagents lyophilized in a single tube in its proprietary Sample-Ready format. The test kits can be shipped globally without refrigeration.
“We are very pleased with the reliability and performance of this complex respiratory panel. The simultaneous detection of COVID-19, Flu A, Flu B and RSV during Flu season would help further augment the BD MAX testing capacity by over 50,000 tests per week,” said Shazi Iqbal, CEO of BioGX.
The testing supplies are sold commercially by Becton, Dickinson and Company, known as BD.
Birmingham’s BioGX, parent of The Netherlands firm, is a provider of lyophilized real-time PCR reagents for molecular diagnostics in the U.S. and elsewhere.
